Large numbers of preclinical rodent models of glioblastoma have assessed the effects of anti-PD-1 immune checkpoint inhibition alone [39] and in combination with various other treatments [26–28, 43], including radiation [26, 43] and temozolomide [43]. The gene discussed is PDCD1; the disease is glioblastoma.